41 results
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
of innovative compounds and the filing of NDAs are significantly greater than those expenses associated with ANDAs. As we continue to develop new
20-F/A
2021 FY
IPCIF
Intellipharmaceutics International Inc.
6 May 22
Annual report (foreign) (amended)
7:54pm
pharmaceuticals in accordance with FDA regulations. Typically, research expenses related to the development of innovative compounds and the filing
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
28 Feb 22
Primary Document
9:56pm
pharmaceuticals in accordance with FDA regulations. Typically, research expenses related to the development of innovative compounds and the filing of NDAs
6-K
EX-99.1
j6smrkna7eboqx41
1 Mar 21
Primary Document
8:21am
6-K
EX-99.1
i4n2vyj
28 Feb 20
Primary Document
4:42pm
6-K
EX-99.1
5cxyd5xru87wpg
4 Mar 19
Primary Document
7:13am
20-F/A
ucg9kroa7sf giyno
4 Mar 19
Annual report (foreign) (amended)
7:05am
6-K
EX-99.1
lmkj4
1 Mar 19
Primary Document
12:00am
424B5
fb9 6nx40
13 Oct 17
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
4c1p gmgl9zq9
27 Feb 15
Current report (foreign)
12:00am
6-K
EX-99.3
hytg1807y9gv575k zh
23 Feb 15
Current report (foreign)
12:00am